ArticleFrontiers in pediatrics2026
Research on the severity of symptoms in children with ASD based on integrated machine learning and structural equation modeling: age-specific predictive features and mediation effect path analysis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The correlation between age at first diagnosis and symptom severity in autism spectrum disorder (ASD) remains inconsistent in existing research, and the age-specific mechanisms through which developmental level and physical development mediate this relationship remain to be elucidated. Methods: A total of 608 children with ASD aged 24∼71 months at first diagnosis were recruited and stratified into a low-age group (24∼47 months) and a high-age group (48∼71 months). The Gesell Developmental Schedule (GDS) was utilized to assess developmental level, the Childhood Autism Rating Scale (CARS) to evaluate symptom severity, and height-for-age Z-score (HAZ), weight-for-age Z-score (WAZ), and body mass index-for-age Z-score (BAZ) were calculated to assess physical development. Integrated machine learning was applied to construct classification models for distinguishing severe from non-severe ASD and to identify age-specific predictive features, and structural equation modeling (SEM) was used to analyze the mediation effects and path mechanisms. Results: Machine learning revealed language as the core predictive feature for the low-age group; whereas in the high-age group, the predictive importance of personal-social, fine motor, gross motor, HAZ, and WAZ increased significantly, with a relative decline in the predictive importance of language. SEM showed a masking effect in the total sample: age at first diagnosis had a positive total indirect effect on symptom severity via developmental level and physical development, but a negative direct effect that offset the total indirect effect, resulting in a non-significant total effect. The mediating role of developmental level was significant, and the effect of developmental level on symptom severity was more pronounced in the low-age group. Conclusion: This study identifies age-specific predictive features-language as the core predictive feature in the low-age group, whereas in the high-age group, the importance of personal-social, motor, and physical development increases while that of language declines. It also reveals a masking effect of age at first diagnosis on ASD symptom severity: a negative direct effect offset by a positive indirect effect via developmental level and physical development, resulting in a non-significant total effect. These findings provide a preliminary reference for age-stratified intervention in children with ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.